Subcutaneous ivermectin treatment in severe strongyloidiasis: is it time to recommend drug concentration measurements and parasitological stool monitoring follow-up?
Strongyloides stercoralis can cause life-threatening infections. Subcutaneous veterinary formulations of ivermectin (IVM) may be the only option for severe treatment, but the dosage and duration are empirical. This article, based on a clinical case, discusses ivermectin concentrations and proposes clinical and parasitological follow-up to guide parenteral therapy in severe strongyloidiasis.
Authors
- Laurent Gétaz (ORCID: https://orcid.org/0000-0002-8724-861X)
- Caroline Bastid
- Andrea Allgöwer
- Sigiriya Aebischer Perone (ORCID: https://orcid.org/0000-0002-4702-8671)
- Gabriel Alcoba (ORCID: https://orcid.org/0000-0002-9423-1533)
- François Chappuis (ORCID: https://orcid.org/0000-0003-0442-7610)
- Anne Lespine (ORCID: https://orcid.org/0000-0001-8153-8555)
- Anne Mauris
- Gilles Éperon
- Jean‐François Sutra
Institutions
- University of Geneva (CH)
- École Nationale Vétérinaire de Toulouse (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- University Hospital of Geneva (CH)
- Geneva College (US)
Publication Details
- Journal
- Journal of Travel Medicine
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1093/jtm/taaf122
- Primary Topic
- Parasites and Host Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00